Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Risk stratification using growth differentiation factor 15 in patients undergoing transcatheter aortic valve implantation

M. Sluka, M. Hutyra, R. Nykl, J. Ostransky, T. Furst, P. Petrova, J. Precek, S. Hudec, M. Taborsky

. 2023 ; 167 (3) : 263-271. [pub] 20220412

Language English Country Czech Republic

Document type Journal Article

AIMS: Growth differentiation factor 15 (GDF15) shows potential predictive value in various cardiac conditions. We investigated relationships between GDF15 and clinical or procedural outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) in order to propose clinically useful predictive risk stratification model. METHODS: This prospective single-center registry enrolled 88 consecutive patients with severe symptomatic aortic stenosis treated with TAVI. Clinical parameters were collected and biomarkers including GDF-15 were measured within 24 h before TAVI. All relevant clinical outcomes according to the Valve Academic Research Consortium-2 were collected over the follow-up period. RESULTS: The cohort included 52.3% of females. The mean age of study participants was 81 years; the mean Society of Thoracic Surgeons (STS) score and logistic EuroSCORE were 3.6% and 15.4%, respectively. The mortality over the entire follow-up period was 10.2%; no death was observed within the first 30 days following TAVI. Univariate analysis showed significant associations between GDF15 and mortality (P=0.0006), bleeding (P=0.0416) and acute kidney injury (P=0.0399). A standard multivariate logistic regression model showed GDF-15 as the only significant predictor of mortality (P=0.003); the odds ratio corresponding to an increase in GDF15 of 1000 pg/mL was 1.22. However, incremental predictive value was not observed when the STS score was combined with GDF15 in this predictive model. CONCLUSIONS: Based on our observations, preprocedural elevated GDF15 levels are associated with increased mortality and demonstrate their additional value in predicting adverse clinical outcomes in a TAVI population.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23018198
003      
CZ-PrNML
005      
20231121092150.0
007      
ta
008      
231107s2023 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2022.017 $2 doi
035    __
$a (PubMed)35416185
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Sluka, Martin $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $7 xx0114481
245    10
$a Risk stratification using growth differentiation factor 15 in patients undergoing transcatheter aortic valve implantation / $c M. Sluka, M. Hutyra, R. Nykl, J. Ostransky, T. Furst, P. Petrova, J. Precek, S. Hudec, M. Taborsky
520    9_
$a AIMS: Growth differentiation factor 15 (GDF15) shows potential predictive value in various cardiac conditions. We investigated relationships between GDF15 and clinical or procedural outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) in order to propose clinically useful predictive risk stratification model. METHODS: This prospective single-center registry enrolled 88 consecutive patients with severe symptomatic aortic stenosis treated with TAVI. Clinical parameters were collected and biomarkers including GDF-15 were measured within 24 h before TAVI. All relevant clinical outcomes according to the Valve Academic Research Consortium-2 were collected over the follow-up period. RESULTS: The cohort included 52.3% of females. The mean age of study participants was 81 years; the mean Society of Thoracic Surgeons (STS) score and logistic EuroSCORE were 3.6% and 15.4%, respectively. The mortality over the entire follow-up period was 10.2%; no death was observed within the first 30 days following TAVI. Univariate analysis showed significant associations between GDF15 and mortality (P=0.0006), bleeding (P=0.0416) and acute kidney injury (P=0.0399). A standard multivariate logistic regression model showed GDF-15 as the only significant predictor of mortality (P=0.003); the odds ratio corresponding to an increase in GDF15 of 1000 pg/mL was 1.22. However, incremental predictive value was not observed when the STS score was combined with GDF15 in this predictive model. CONCLUSIONS: Based on our observations, preprocedural elevated GDF15 levels are associated with increased mortality and demonstrate their additional value in predicting adverse clinical outcomes in a TAVI population.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a transkatetrální implantace aortální chlopně $x škodlivé účinky $7 D065467
650    _2
$a růstový diferenciační faktor 15 $7 D055436
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    12
$a aortální stenóza $x chirurgie $7 D001024
650    _2
$a výsledek terapie $7 D016896
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hutyra, Martin, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $d 1974- $7 xx0013232
700    1_
$a Nykl, Radomír $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $7 xx0227522
700    1_
$a Ostransky, Jiri $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic
700    1_
$a Furst, Tomas $u Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science, Palacky University Olomouc, Czech Republic
700    1_
$a Petrová, Pavla $u Department of Clinical Biochemistry, University Hospital Olomouc, Czech Republic $7 xx0166833
700    1_
$a Přeček, Jan, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $d 1985- $7 xx0154445
700    1_
$a Hudec, Štěpán $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $7 xx0227664
700    1_
$a Táborský, Miloš, $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic $d 1962- $7 jn20010310074
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 167, č. 3 (2023), s. 263-271
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35416185 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20231107 $b ABA008
991    __
$a 20231121092147 $b ABA008
999    __
$a ok $b bmc $g 2011499 $s 1204601
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 167 $c 3 $d 263-271 $e 20220412 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK198 $a Pubmed-20231107

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...